A Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy

A Prospective Observational Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy

The trial was designed as a single-center, non-interventional, prospective observational study to explore the role of a multimodal digital device in analyzing subjective and objective recovery in lung cancer patients undergoing sublobar resection versus lobectomy.

Study Overview

• Status: Recruiting
• Conditions: Lobectomy; Lung Cancer (Diagnosis); Sublobar Resection

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: Jianxing He, M.D.; Phone Number: +86-20-83337792; Email: drjianxing.he@gmail.com
• Study Contact Backup: Name: Hengrui Liang, M.D.; Phone Number: +86-20-83062114; Email: liang_hengrui@163.com

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China
      • Recruiting
      • Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University
      • Contact: Hengrui Liang, M.D.; Phone Number: +86-020-83062807; Email: liang_hengrui@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients with histopathologically confirmed lung cancer were consecutively recruited

Description

Inclusion Criteria:

1. adult patients (age ≥ 18 years)
2. American Society of Anesthesiologists (ASA) grade of III or below
3. scheduled for VATS from March to December 2023

Exclusion Criteria:

1. age <18 years
2. inability or poor compliance to use wearable devices
3. lack of smartphone
4. incomplete digital device data during hospitalization
5. patients with lymph node or distant metastasis

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Sublobar Resection Group; Patients in this group underwent sublobar resection (including segmentectomy or wedge resection). The decision for patients to receive this surgical procedure was similarly based on their routine clinical assessment, disease characteristics, physician's recommendation, and informed consent. It was not a result of randomization or active intervention by the investigators. This study will prospectively observe the post-operative recovery and prognosis of these patients, comparing them to the lobectomy group.
Lobectomy Group; Patients in this group underwent standard lobectomy. The decision for patients to receive this surgical procedure was based on their routine clinical assessment, diagnosis, disease staging, physician's recommendation, and informed consent. It was not a result of randomization or active intervention by the investigators. This study will prospectively observe the post-operative recovery and prognosis of these patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Electronic patient-reported outcomes	The electronic patient-reported outcomes questionnaire includes pain, cough, shortness of breath, restless sleep, fatigue, drowsiness, walking difficulties, activity limitation, and distress(0 = no symptom, 10 = most severe).	From 1 day prior to surgery through hospital discharge (assessed up to 15 days).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Length of Hospital Stay	Total number of days spent in the hospital from admission to discharge.	From the day of surgery until the day of discharge, assessed up to 15 days.
Surgical Time	Duration of the surgery measured in hours.	During the surgical procedure (from anesthesia induction until skin closure).
Number of Lymph Nodes Dissected	The total count of lymph nodes harvested during the surgical procedure.	During the surgical procedure (from anesthesia induction until skin closure).

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Study record dates

Study Major Dates

• Study Start (Actual): March 9, 2023
• Primary Completion (Estimated): December 10, 2025
• Study Completion (Estimated): April 20, 2026

Study Registration Dates

• First Submitted: November 19, 2025
• First Submitted That Met QC Criteria: December 15, 2025
• First Posted (Actual): December 17, 2025

Study Record Updates

• Last Update Posted (Actual): December 17, 2025
• Last Update Submitted That Met QC Criteria: December 15, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Pathological Conditions, Signs and Symptoms; Lung Neoplasms; Disease
• Other Study ID Numbers: GMU-LC-202511

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No